Weight-gain in psychiatric treatment: Risks, implications, and strategies for prevention and management

Mens Sana Monographs

Volumn 8, Issue 1, 2010, Pages 53-68

  Shrivastava, Amresh ^a   Johnston, Megan E ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Antipsychotics; Psychiatric patients; Psychopharmacology; Treatment induced weight gain; Weight gain

Indexed keywords

EID: 75649132893     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.58819     Document Type: Article

References (60)

1. Ackerman S., Nolan L.J., (1998), Bodyweight-gain induced by psychotropic drugs: incidence, mechanisms, and management, CNS Drugs, 9(2), p135-151.
2. Afshar H., Roohafza H., Mousavi G., Golchin S., Toghianifar N., Sadeghi M., Talaei M., (2009), Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial, J Psychopharmacol, 23(2), p157-162.
3. Amiel J.M., Mangurian C.V., Ganguli R., Newcomer J.W., (2008), Addressing cardiometabolic risk during treatment with antipsychotic medications, Curr Opin Psychiatry, 21(6), p613-618.
4. Apfelbaum M., Vague P., Ziegler O., Hanotin C., Thomas F., Leutenegger E., (1999), Longterm maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine, Am J Med, 106(2), p179-184.
5. Allison D.B., Loebel A.D., Lombardo I., Romano S.J., Siu C.O., (2009), Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean? Psychiatry Res, 170(3) p172-176.
6. Arman S., Sadramely M.R., Nadi M., Koleini N., (2008), A randomized, double-blind, placebo-controlled trial of metformin treatment for weight-gain associated with initiation of risperidone in children and adolescents, Saudi Med J, 29(8), p1130-1134.
7. Astrup A., Toubro S., Cannon S., Hein P., Madsen J., (1991), Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study, Metabolism, 40(3), p323-329.
8. Bean M.K., Stewart K., Olbrisch M.E., (2008), Obesity in America: Implications for clinical and health psychologists, J Clin Psychol in Medical Settings, 15(3), p214-224.
9. Bergen D.C., Ristanovic R.K., Waicosky K., Kanner A., Hoeppner T.J., (1995), Weight loss in patients taking felbamate, Clin Neuropharmacology, 18(1), p23-27.
10. Bhuvaneswar C.G., Baldessarini R.J., Harsh V.L., Alpert J.E., (2009), Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review, CNS Drugs, 23 (12), p1003-1021
11. Boney C.M., Verma A., Tucker R., Vohr B.R., (2005), Metabolic syndrome in childhood: associations with birth weight, maternal obesity, and gestational diabetes mellitus, Pediatrics, 115(3), p290-296.
12. Bray G.A., (2007), Drug treatment of the overweight patient, Gastroenterology, 132(6), p2239-2252.
13. Brost B.C., Goldenberg R.L., Mercer B.M., Iams J.D., Meis P.J., Moawad A.H., et al., (1997), The preterm prediction study: association of cesarean delivery with increases in maternal weight and body mass index, Am J Obstet Gynecol, 177(2), p333-337.
14. Centorrino F., Wurtman J.J., Duca K.A., Fellman V.H., Fogarty K.V., Berry J.M., et al., (2006), Weight loss in overweight patients maintained on atypical antipsychotic agents, Int J Obes, 30(6), p1011-1016.
15. Chen C.H., Chiu C.C., Huang M.C., Wu T.H., Liu H.C., Lu M.L., (2008), Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine, Prog Neuropsychopharmacol Biol Psychiatry, 32(4) p925-931
16. Citrome L., Vreeland B., (2009), Obesity and mental illness, Mod Trends Pharmacopsychiatry, 26, p25-46.
17. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra., (2009), Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents, J Am Med Assoc, 302(16), p1765-1773.
18. Dursun S.M., Devarajan S., (2000) Clozapine weight-gain, plus topiramate weight loss, Can J Psychiatry 45, p198.
19. Fagiolini A., Frank E., Houck P.R., Mallinger A.G., Swartz H.A., Buysse D.J., et al., (2002), Prevalence of obesity and weight change during treatment in patients with bipolar I disorder, J Clin Psychiatry, 63(6), p528-33.
20. Faulkner G., Cohn T.A., (2006), Pharmacologic and nonpharmacologic strategies for weightgain and metabolic disturbance in patients treated with antipsychotic medications, Can J Psychiatry, 51(8), p502-511.
21. Faulkner G., Cohn T., Remington G., (2007), Interventions to reduce weight-gain in schizophrenia, Schizophr Bull, 33(3), p654-656.
22. Fava M., (2000), Weight-gain and antidepressants, J Clin Psychiatry, 61(Suppl 11), p37-41.
23. Fernstrom M., Epstein L.H., Spiker D.G., Kupfer D.J., (1985), Resting metabolic rate is reduced in patients treated with antidepressants, Biol Psychiatry, 20(6), p688-692.
24. Finer N., James W.P., Kopelman P.G., Lean M.E., Williams G., (2000), One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor, Int J Obes Relat Metab Disord, 24, p306-313.
25. Floris M., Lejeune J., Deberdt W., (2001), Effect of amantadine on weight-gain during olanzapine treatment, Eur Neuropsychopharmacol, 11(2), p181-182.
26. Garland E.J., Remick R.A., Zis A.P., (1988), Weight-gain with antidepressants and lithium, J Clin Psychopharmacol, 8(5), p323-330.
27. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.C., et al., (2009), Antipsychotic-induced body weight-gain: predictors and a systematic categorization of the long-term weight course, J Psychiatr Res, 43(6), p620-626.
28. Goeree R., Farahati F., Burke N., Blackhouse G., O'Reilly D., Pyne J., et al., (2005), The economic burden of schizophrenia in Canada in 2004, Curr Med Res Opin, 21(12), p2017-2028.
29. Gordon A., Price L.H., (1999), Mood stabilization and weight loss with topiramate, Am J Psychiatry, 156(6), p968-968.
30. Gustafson D., (2008), A life course of adiposity and dementia, Eur J Pharmacol, 6(1), p163- 175.
31. Haddad P., (2005), Weight change with atypical antipsychotics in the treatment of schizophrenia, J Psychopharmacol, 19(6 Suppl), p16-27.
32. Hebebrand M.D., Hinney A., (2009), Environmental and genetic risk factors in obesity, Child Adolesc Psychiatr Clin N Am, 18(1), p83-94.
33. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H., (2007), Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects, Neuropsychopharmacology, 32, p289-297.
34. Howard L.M., (2005), Fertility and pregnancy in women with psychotic disorders, Eur J Obstet Gynecol Reprod Biol, 119(1), p3-10.
35. Jelalian E., Wember Y.M., Bungeroth H., Birmaher V., (2007), Practitioner review: Bridging the gap between research and clinical practice in pediatric obesity, J Child Psychol Psychiatry, 48(2), p115-127.
36. Jin H., Meyer J.M., Mudaliar S., Jeste D.V., (2008), Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponecti, Schizophr Res, 100(1-3), p70-85.
37. Kerwin R., (2009), Connecting patient needs with treatment management, Acta Psychiatr Scand, 119 (Suppl. 438), p33-39.
38. Korner J., Aronne L.J., (2003), The emerging science of body weight regulation and its impact on obesity treatment, J Clin Invest, 111(5), p565-570.
39. Kristensen J., Vestergaard M., Wisborg K., Kesmodel U., Secher N.J., (2005), Pre-pregnancy weight and the risk of stillbirth and neonatal death, Br J Obstet Gynaecol, 112, p403-408.
40. Livingstone C., Rampes H., (2006), Lithium: a review of its metabolic adverse effects. J Psychopharmacology, 20(3), p347-355.
41. McKenna K., Koren G., Tetelbaum M., Wilton L., Shakir S., Diav-Citrin O., et al., (2005), Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study, J Clin Psychiatry, 66(4), p444-449. (Pubitemid 40593572)
42. Michelson J., Bancroft S., Targum S., Yongman K., Tepner R., (2000), Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention, Am J Psychiatry 157(2), p239-243.
43. Moller H.J., (2008), Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment, World J Biol Psychiatry, 9(2), p102-114.
44. Monteleone P., Martiadis V., Maj M., (2009), Management of schizophrenia with obesity, metabolic, and endocrinological disorders, Psychiatr Clin North Am, 32(4) p775-794.
45. Morrison J.A., Cottingham E.M., Barton B.A., (2002), Metformin for weight loss in pediatric patients taking psychotropic drugs, Am J Psychiatry, 159(4), p655-657.
46. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.(2009), Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes, Diabetes Care, 32(6), p1037-1042. Epub 2009 Feb 24.
47. Mushtaq F., Mondelli V., Pariante C.M., (2008), The metabolic implications of long term cannabis use in patients with psychosis, Epidemiol Psychiatr Soc, 17(3), p221-226.
48. Newcomer J.W., (2007), Metabolic considerations in the use of antipsychotic medications: A review of recent evidence, J Clin Psychiatry, 68(Suppl 1), p20-27.
49. Payer J., Hainer V., Ondrejka P., Kajtor Z., (2004), Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)], Vnitr Lek, 50(11), p825-829.
50. Saddichha S., Ameen S., Akhtar S., (2008), Predictors of antipsychotic-induced weightgain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol, J Clin Psychopharmacol, 28(1), p27-31.
51. Shi H., Clegg D.J., (2009), Sex differences in the regulation of body weight, Physiol Behav, 97(2), p199-204.
52. Silverstone T., Smith G., Goodall E., (1988), Prevalence of obesity in patients receiving depot antipsychotics, Br J Psychiatry, 153, p214-217.
53. Simon V., van Winkel R., De Hert M., (2009), Are weight-gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review, J Clin Psychiatry, 70(7), p1041- 50.
54. Tarricone I., Ferrari Gozzi B., Serretti A., Grieco D., Berardi D., (2009), Weight-gain in antipsychotic-naive patients: a review and meta-analysis, Psychol Med, 6, p1-14.
55. Umbricht D.S., Pollack S., Kane J.M., (1994), Clozapine and weight-gain, J Clin Psychiatry, 55 (Suppl B), p157-60.
56. Vestergaard P., Amidson A., Schou M., (1980), Clinically signifi cant side effects of lithium treatment, Acta Psychiatr Scand, 62(3), p193-200.
57. Wadden T.A., Butryn M.L., Wilson C., (2007), Lifestyle modification for the management of obesity, Gastroenterology, 132(6), p2226-2238.
58. Weber M., Wyne K., (2006)A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotic, Schizophr Res, 83(1), p95-101.
59. Wetterling T., (2001), Bodyweight-gain with atypical antipsychotics: A comparative review, Drug Saf, 24(1), p59-73.
60. Zimmermann U., Rechlin T., Plaskacewicz G., Barocka A., Wildt L., Kaschka W., (1997), Effect of naltrexone on weight-gain and food craving induced by tricyclic antidepressants and lithium: An open study, Bio Psychiatry, 41(6), p747-749.